Page 89 - The autoimmune hypothesis of narcolepsy and its unexplored clinical features M.S. Schinkelshoek

BMI decreases in patient groups between first and last measurement
Four separate groups were constructed based on treatment and gender. Those treated with SXB lost weight during follow-up (-1.58 kg/m2, SD 2.12 kg/m2; p < 0.001; Figure 5.1 and Figure 5.2). Women using SXB lost weight with a mean BMI decrease of 2.56 kg/m2 (SD 2.20 kg/m2; p = 0.001) which corresponds to an average weight loss of 7.1 kg; men with a mean BMI decrease of 0.84 kg/m2 (SD 1.71 kg/m2; p = 0.006) which corresponds to 2.8 kg. Patients using modafinil, however, gained weight (0.60 kg/m2, SD 0.91 kg/m2; p = 0.005). A mean BMI increase of 0.57 kg/m2 (SD 0.96 kg/m2; 1.6 kg) was found in women (p = 0.033), while a mean BMI increase of 0.67 (SD 0.88 kg/m2; 2.3 kg) was observed in men (p = 0.122). After adjustment for multiple testing BMI decrease in women using modafinil failed to reach statistical significance.
Figure 5.1. Body mass index (BMI) values at baseline and at last follow-up of patients in whom treatment with sodium oxybate (SXB; red, N = 59) and patients in whom treatment with modafinil (green, N = 22) was newly started. Each data point represents one patient at either baseline or follow-up. Individual values per patient are linked.
Medication and BMI change
87
5